natgillin/translations-raw huggingface dataset:
Pregabalin Zentiva 150 mg hard capsules are packed into PVC/alu blisters as primary packaging.
Pregabalin Zentiva 150 mg tvrde kapsule zapakirane su u PVC/alu blistere kao primarno pakiranje.
Pregabalin Zentiva 200 mg hard capsules are packed into PVC/alu blisters as primary packaging.
Pregabalin Zentiva 200 mg tvrde kapsule zapakirane su u PVC/alu blistere kao primarno pakiranje.
Pregabalin Zentiva 225 mg hard capsules are packed into PVC/alu blisters as primary packaging.
Pregabalin Zentiva 225 mg tvrde kapsule zapakirane su u PVC/alu blistere kao primarno pakiranje.
Pregabalin Zentiva 25 mg and 50 mg is available in pack of 14, 21, 56, 84 and 100 hard capsules.
Pregabalin Zentiva 25 mg i 50 mg dostupni su u pakiranjima od 14, 21, 56, 84 i 100 tvrdih kapsula.
Pregabalin Zentiva 300 mg hard capsules are packed into PVC/alu blisters as primary packaging.
Pregabalin Zentiva 300 mg tvrde kapsule zapakirane su u PVC/alu blistere kao primarno pakiranje.
Pregabalin Zentiva 50 mg hard capsules are packed into PVC/alu blisters as primary packaging.
Pregabalin Zentiva 50 mg tvrde kapsule zapakirane su u PVC/alu blistere kao primarno pakiranje.
Pregabalin Zentiva 75 mg hard capsules are packed into PVC/alu blisters as primary packaging.
Pregabalin Zentiva 75 mg tvrde kapsule zapakirane su u PVC/alu blistere kao primarno pakiranje.
Pregabalin Zentiva 75 mg, 150 mg, 225 mg and 300 mg is available in pack of 14, 56 and 100 hard capsules.
Pregabalin Zentiva 75 mg, 150 mg, 225 mg i 300 mg dostupni su u pakiranjima od 14, 56 i 100 tvrdih kapsula.
Pregabalin Zentiva belongs to a group of medicines used to treat epilepsy and generalised anxiety disorder (GAD) in adults.
Pregabalin Zentiva pripada skupini lijekova koji se koriste za liječenja epilepsije i generaliziranog anksioznog poremećaja (GAP) u odraslih osoba.
Pregabalin Zentiva contains lactose monohydrate
Pregabalin Zentiva sadrži laktozu hidrat
Pregabalin Zentiva hard capsules may be taken with or without food.
Pregabalin Zentiva tvrde kapsule mogu se uzimati s hranom ili bez nje.
Pregabalin Zentiva is a ‘generic medicine’.
Pregabalin Zentiva je „generički lijek”.
Pregabalin Zentiva is for oral use only.
Pregabalin Zentiva je namijenjen samo za primjenu kroz usta.
Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults.
Pregabalin Zentiva indiciran je za liječenje generaliziranog anksioznog poremećaja (GAP) u odraslih osoba.
Pregabalin Zentiva with food, drink and alcohol
Pregabalin Zentiva s hranom, pićem i alkoholom
Pregelatinised maize starch Colloidal anhydrous silica Stearic acid
kukuruzni škrob, prethodno geliran silicijev dioksid, koloidni, bezvodni stearatna kiselina talk
Pregelatinised starch (derived from maize starch) Talc
škrob (kukuruzni), prethodno geliran, talk,
Pregelatinised starch Croscarmellose sodium Lactose monohydrate Talc
škrob, prethodno geliran karmelozanatrij, umrežena laktoza hidrat
Pregnancies have occurred in women taking efavirenz, a component of Atripla, while using a contraceptive implant, although it has not been established that the efavirenz therapy caused the contraceptive to fail.
Zabilježeni su slučajevi trudnoća u žena koje su uzimale komponentu Atriple efavirenz, a istovremeno su koristile i kontraceptivni implantat, iako nije ustanovljeno da je terapija efavirenzom uzrokovala neučinkovitost kontraceptiva.
Pregnancy
budezonid.
Pregnancy
glutamiltransferaza1
Pregnancy
Graviditet:
Pregnancy
Karcinogenost
Pregnancy
Lopinavir:
Pregnancy
Pušači
Pregnancy
Srčani poremećaji
Pregnancy
Trudoća
Pregnancy (see section 4.6)
Trudnoća (vidjeti dio 4.6)
Pregnancy (see section 4.6)
Trudnoća (vidjeti odjeljak 4.6)
Pregnancy (see section 4.6).
U trudnoći (vidjeti dio 4.6).
Pregnancy (see sections 4.4 and 4.6)
Trudnoća (vidjeti dijelove 4.4 i 4.6)
Pregnancy (see sections 4.4, 4.6 and 5.3).
Trudnoća (vidjeti dijelove 4.4, 4.6 i 5.3).
Pregnancy (see sections 4.6 and 5.3).
Trudnoća (vidjeti dio 4.6 i 5.3).
Pregnancy and any exposure during pregnancy must be avoided.
Mora se izbjegavati trudnoća i bilo kakvo izlaganje lijeku tijekom trudnoće.
Pregnancy and bre ast-feeding
Trudnoća i dojenje
Pregnancy and breast feeding (see section 4.6).
Trudnoća i dojenje (vidjeti dio 4.6).
Pregnancy and breast--feeding
Trudnoća i dojenje
Pregnancy and breast-feeding (see section 4.6)
Trudnoća i dojenje (vidjeti dio 4.6)
Pregnancy and breast-feeding (see sections 4.4 and 4.6)
Trudnoća i dojenje (vidjeti dijelove 4.4 i 4.6).
Pregnancy and breast-feeding.
Trudnoća i dojenje
Pregnancy and breast–feeding
Trudnoća i dojenje
Pregnancy and contraception in females
Trudnoća i kontracepcija u žena
Pregnancy and contraception requirements
Trudnoća i kontracepcija
Pregnancy and lactation
Plodnost, trudnoća i dojenje
Pregnancy and lactation
Trudnoća i dojenje
Pregnancy and lactation (see section 4.6).
Trudnoća i dojenja (vidjeti dio 4.6).
Pregnancy and lactation :
Graviditet i laktacija:
Pregnancy and lactation:
Graviditet i laktacija;
Pregnancy and lactation:
Graviditeta i laktacije
Pregnancy and lactation:
Gravidnost i laktacija:
Pregnancy and lactation:
Primjena tijekom graviditeta i laktacije:
Pregnancy and Women of childbearing potential
Trudnoća i žene reproduktivne dobi
Pregnancy and women of childbearing potential
Trudnoća i žene u reproduktivnoj dobi
Pregnancy initial and outcome reporting forms
obrasce za prijavljivanje trudnoće – početne i one za prijavljivanje ishoda
Pregnancy may occasionally occur after ellaOne intake.
Nakon uzimanja ellaOne ponekad može doći do trudnoće.
Pregnancy must be excluded before start of treatment with leflunomide.
Prije liječenja leflunomidom mora se isključiti trudnoća
Pregnancy or breast-feeding.
Trudnoća ili dojenje.
Pregnancy or lactation
Graviditet i laktacija
Pregnancy outcomes, in patients treated with Jinarc
glaukoma ishodima trudnoća u bolesnica liječenih Jinarcom
Pregnancy Prevention Programme information
informacije o Programu prevencije trudnoće
Pregnancy prevention requirement, definition and need for adequate contraceptive methods
zahtjev za prevencijom trudnoće, definiciju i potrebu za odgovarajućim metodama kontracepcije
Pregnancy rate
Stopa trudnoća
Pregnancy rate (%) within 72h of unprotected intercourse or contraceptive failure2
Stopa trudnoće (%) unutar 72 sata od nezaštićenog snošaja ili zatajenja kontracepcijske metode2
Pregnancy reporting forms
Formular za dojavu u slučaju trudnoće
Pregnancy test if female patient with child-bearing potential.
Testiranje na trudnoću za žene reproduktivne dobi.
Pregnancy test regime
režim testiranja na trudnoću
Pregnancy testing requirements
zahtjevi za testove na trudnoću:
Pregnancy tests should be repeated as clinically required (e.g. after any gap in contraception is reported.
Testovi na trudnoću moraju se ponavljati sukladno kliničkoj indikaciji (npr. nakon prijave bilo kakvog odstupanja u kontracepciji).
Pregnancy – information for men
Trudnoća – informacije za muškarce
Pregnancy – information for women
Trudnoća – informacije za žene
Pregnancy, bre ast-feeding and fertility
Trudnoća, dojenje i plodnost
Pregnancy, breast-feeding
Trudnoća i dojenje
Pregnancy, breast-feeding and contraception - information for women and men Pregnancy
Trudnoća, dojenje i kontracepcija – informacije za žene i muškarce Trudnoća
Pregnancy, breast-feeding and fertility
Trudnoća,dojenje i plodnost
Pregnancy, breast-feeding and fertility Pregnancy
Trudnoća, dojenje i plodnost Trudnoća
Pregnancy, contraception and breast-feeding if you are pregnant, tell your doctor before you start taking RAVICTI.
Trudnoća, kontracepcija i dojenje ako ste trudni, recite to svom liječniku prije početka uzimanja lijeka RAVICTI.
Pregnancy, contraception and breast-feeding – information for women and men
Trudnoća, kontracepcija i dojenje – obavijesti za žene i muškarce
Pregnancy, lactation and Fertility:
Gravidnost, laktacija i plodnost:
Pregnancy, lactation and Fertility:
Gravidnost, laktacija, plodnost:
Pregnancy, lactation and women of child-bearing potential not using appropriate contraceptive measures (see section 4.6)
Trudnoća, dojenje i žene generativne dobi koje ne koriste prikladne mjere kontracepcije (vidjeti dio 4.6)
Pregnancy, lactation, Fertility:
Gravidnost, laktacija i plodnost:
Pregnancy, lactation:
Graviditet, laktacija:
Pregnancy, puerperium and perinatal
boje kože,seboroični
Pregnancy, puerperium and perinatal
Stanja vezana uz trudnoću, babinje i
Pregnancy, puerperium and perinatal
Stanja vezana uz trudnoću, babinje i perinatalno razdoblje
Pregnancy, puerperium and perinatal
uz trudnoću, babinje i
Pregnancy, puerperium and perinatal conditions
Stanja vezana uz trudnoću, babinje i
Pregnancy/contraception
Trudnoća/kontacepcija
Pregnancy/Lactation:
Graviditet i laktacija:
Pregnancy:
Graviditete:
Pregnancy:
Primjena tijekom graviditeta
Pregnancy: The use of memantine in pregnant women is not recommended.
Trudnoća: trudnicama se ne preporučuje upotreba memantina.
Pregnancy: there are no adequate data from the use of bexarotene in pregnant women.
Trudnoća: Nema odgovarajućih podataka o primjeni beksarotena u trudnica.
Pregnancy: there are no adequate data from the use of entecavir in pregnant women.
Trudnoća: nema odgovarajućih podataka o primjeni entekavira u trudnica.
Pregnancy: There are no adequate data from the use of ranolazine in pregnant women.
Trudnoća: Nema podataka o primjeni ranolazina kod trudnica.
Pregnancyand breast-feeding
Trudnoća i dojenje
Pregnancyand, breast-feeding
Trudnoća i dojenje
Pregnane X Receptor (PXR) regulated enzyme interactions other than CYP3A4 have not been studied.
Interakcije za druge enzime regulirane receptorom za pregnan- X, osim za CYP3A4, nisu ispitane.
Pregnant and breast-feeding women must not come into contact with the product and should also avoid operating rooms and animal recovery areas where the product is being, or has recently been, used.
Trudnice i dojilje ne smiju imati nikakav dodir s ovim proizvodom te moraju izbjegavati operacijske dvorane i prostorije za oporavak životinja u kojima se proizvod koristi ili se nedavno koristio.
Pregnant and breast-feeding women should not have any contact with the product and should avoid operating rooms and animal recovery areas.
Trudnice i dojilje ne smiju imati nikakav dodir s ovim proizvodom i moraju izbjegavati operacijske dvorane i prostorije za oporavak životinja.
Pregnant and lactating women
Trudnice i dojilje
Pregnant or breast-feeding mothers must not take PREZISTA unless specifically directed by the doctor.
Trudnice ili dojilje ne smiju uzimati lijek PREZISTA osim ako to liječnik posebno ne odredi.
Pregnant or breastfeeding women and women attempting to conceive should avoid contact with the solution and should be prevented from an accidental self-injection. (There are no data on pregnancy outcome in humans following injection of cabergoline, but studies in laboratory animals have shown a risk for embryonic death following repeat oral exposure to cabergoline.)
Trudnice ili žene koje doje te žene koje pokušavaju začeti trebaju izbjegavati kontakt s otopinom i spriječiti slučajno samoinjiciranje. (Nema podataka o ishodu trudnoće u ljudi nakon injiciranja kabergolina, ali su ispitivanja na laboratorijskim životinjama pokazala da postoji rizik od smrti embrija nakon ponovljene peroralne izloženosti kabergolinu.)
pregnant or breastfeeding women;
u trudnica ili dojilja;
Pregnant rabbits treated orally with 7.5 mg/kg/day (7500 times the recommended ophthalmic dose) caused increased post- implantation loss (see section 4.6).
Gravidni kunići, liječeni oralno sa 7,5 mg/kg/dan (7500 puta više od preporučene oftalmološke doze) pokazali su povećani postimplantacijski gubitak fetusa (vidjeti dio 4.6).
Pregnant staff should be excluded from handling the medicinal product.
Trudne djelatnice treba isključiti iz rukovanja lijekom.
Pregnant staff should be excluded from working with this medicinal product.
Trudne zdravstvene djelatnice ne smiju raditi s ovim lijekom.
Pregnant staff should be excluded from working with this medicinal product.
Trudnice ne bi smjele rukovati ovim lijekom.
Pregnant staff should be excluded from working with this medicine
trudne djelatnice ne smiju rukovati ovim lijekom
Pregnant staff should not handle Abraxane.
Trudne zdravstvene radnice ne smiju rukovati ovim lijekom.
Pregnant staff should not handle it.
Zdravstvene djelatnice koje su trudne ne smiju rukovati ovim lijekom.
Pregnant staff should not handle ONIVYDE considering the cytotoxic nature of the medicinal product.
Trudno osoblje ne smije rukovati lijekom ONIVYDE imajući u vidu citotoksičnu prirodu ovog lijeka.
Pregnant staff should not handle ONIVYDE.
Trudno osoblje ne smije rukovati lijekom ONIVYDE.
Pregnant staff should not handle the cytotoxic preparation.
Trudne djelatnice ne smiju rukovati citotoksičnim pripravkom.
Pregnant staff should not handle the product.
Zdravstvene djelatnice koje su trudne ne smiju rukovati ovim lijekom.
Pregnant Women
Trudnice
Pregnant women (see section 4.6)
Trudnice (vidjeti dio 4.6)
Pregnant women (see section 4.6).
Trudnice (vidjeti dio 4.6).
Pregnant women (see sections 4.4, 4.6 and 5.3).
Trudnice (vidjeti dijelove 4.4, 4.6 i 5.3).
Pregnant women and women of child- bearing potential should not administer this product.
Trudnice i žene koje mogu zatrudnjeti ne bi trebale primjenjivati veterinarsko-medicinski proizvod.
Pregnant women may receive oseltamivir, after considering the available safety information, the pathogenicity of the circulating influenza virus strain and the underlying condition of the pregnant woman.
Trudnice mogu primiti oseltamivir nakon razmatranja dostupnih podataka o sigurnosti, patogenosti cirkulirajućeg soja virusa gripe i općeg stanja trudnice.
Pregnant women may receive Tamiflu, after considering the available safety information, the pathogenicity of the circulating influenza virus strain and the underlying condition of the pregnant woman.
Trudnice mogu primiti Tamiflu nakon razmatranja dostupnih podataka o sigurnosti, patogenosti cirkulirajućeg soja virusa gripe i općeg stanja trudnice.
Pregnant women must not take this medicine.
Trudnice ne smiju uzimati ovaj lijek.
Pregnant women must take extra precautions when handling this product.
Trudnice trebaju biti vrlo oprezne prilikom rukovanja proizvodom.
Pregnant women must take extra precautions when handling this veterinary medicinal product.
Trudnice trebaju biti vrlo oprezne prilikom rukovanja ovim proizvodom.
Pregnant women should administer the product with special caution to avoid self-injection since uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure.
Trudnice trebaju s velikom opreznošću primjenjivati proizvod kako bi se izbjeglo samoinjiciranje, jer nakon slučajne sustavne izloženosti može doći do kontrakcija maternice i sniženja krvnog tlaka u fetalnom krvotoku.
Pregnant women should not administer the veterinary medicinal product.
Trudnice ne smiju primjenjivati ovaj VMP.
Pregnant women should not be vaccinated with ProQuad.
Trudnice se ne smiju cijepiti cjepivom ProQuad.
Pregnant women should not take EDURANT unless specifically directed by the doctor.
Trudnice ne smiju uzimati EDURANT ukoliko to liječnik posebno ne odredi.
Pregnant women should take special care to avoid accidental oral exposure because ACE inhibitors have been found to affect the unborn child during pregnancy in humans.
Trudnice posebno trebaju biti posebno pažljive kako bi izbjegle slučajnu peroralnu izloženost jer je utvrđeno da ACE inhibitori utječu na nerođeno dijete tijekom humane trudnoće.
Pregnant women should take special care to avoid accidentally swallowing Fortekor Plus because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy.
Trudnice trebaju posebno paziti da izbjegnu slučajno gutanje VMP-a Fortekor Plus jer je otkriveno da inhibitori enzima koji konvertiraju angiotenzin (ACE) utječu na nerođeno dijete tijekom trudnoće.
Pregnant women should take special care to avoid contact with the product because substances acting on the RAAS, such as Angiotensin Receptor Blockers (ARBs) and ACE inhibitors (ACEi), have been found to affect the unborn child during pregnancy in humans.
Trudnice moraju osobito paziti da izbjegavaju doticaj s ovim proizvodom jer je ustanovljeno da tvari koje djeluju na sustav renin-angiotenzin-aldosteron, kao što su blokatori angiotenzinskih receptora (ARB) i inhibitori acetilkolinesteraze (ACEi), utječu na nerođeno dijete tijekom trudnoće u ljudi.
Pregnant women who have either not had chickenpox or have not been vaccinated against chickenpox.
Trudnice koje nisu preboljele ili nisu cijepljene protiv vodenih kozica.
Pregnant women with mechanical prosthetic heart valves may be at higher risk for thromboembolism.
Trudnice s mehaničkim protezama srčanih zalistaka mogle bi imati povećani rizik za tromboemboliju.
pregnant women without documented positive history of varicella (chickenpox) or laboratory evidence of prior infection, newborn infants of mothers without documented positive history of varicella or laboratory evidence of prior infection.
trudnice bez dokumentirane pozitivne anamneze na varičelu (vodene kozice) ili laboratorijskog dokaza prethodne infekcije, novorođenčad majki bez dokumentirane pozitivne anamneze na varičelu ili laboratorijskog dokaza prethodne infekcije.
Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with leflunomide and thereafter as long as the plasma levels of the active metabolite are above 0.02 mg/l (see section 4.6).
Trudnice i žene generativne dobi koje ne koriste učinkovitu kontracepciju tijekom liječenja leflunomidom i nakon njega, sve dok je koncentracija aktivnog metabolita u plazmi veća od 0,02 mg/l (vidjeti dio 4.6.).
Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with leflunomide and thereafter as long as the plasma levels of the active metabolite are above 0.02 mg/L (see section 4.6).
Trudnice i žene reproduktivne dobi koje ne koriste učinkovitu kontracepciju tijekom liječenja leflunomidom i nakon njega, sve dok je koncentracija aktivnog metabolita u plazmi veća od 0,02 mg/l (vidjeti dio 4.6).
Pregnant women:
Trudnice:
Preliminary data from a supportive study are consistent with the result of the main study, with 46% of patients responding to treatment after 12 weeks.
46 % bolesnika odgovorilo je na terapiju nakon 12 tjedana.
Preliminary data from England and Wales reported less than 1 year following introduction of routine immunisation at 2, 4 and 13 months with a single dose catch-up programme for children 13 to 23 months of age have suggested that effectiveness of this schedule might be lower against serotype 6B than against the other serotypes in the vaccine.
Preliminarni podaci i Engleske i Walesa zabilježeni manje od 1 godine nakon uvođenja rutinske imunizacije u dobi od 2, 4 i 13 mjeseci s programom nadoknade jednokratnom dozom za djecu u dobi od 13 do 23 mjeseca pokazuju da bi učinkovitost ovog rasporeda mogla biti slabija protiv serotipa 6B nego protiv drugih serotipova cjepiva.
Preliminary data from England and Wales reported less than 1 year following introduction of routine immunisation at 2, 4 and 13 months with a single dose catch-up programme for children 13 to 23 months of age have suggested that effectiveness of this schedule might be lower against serotype 6B than against the other serotypes in the vaccine.
Preliminarni podaci iz Engleske i Walesa zabilježeni manje od 1 godine nakon uvođenja rutinske imunizacije u dobi od 2, 4 i 13 mjeseci s programom nadoknade jednokratnom dozom za djecu u dobi od 13 do 23 mjeseca pokazuju da bi učinkovitost ovog rasporeda mogla biti slabija protiv serotipa 6B nego protiv drugih serotipova cjepiva.
Preliminary data from spontaneously reported events and ongoing post-marketing studies (pregnancy registry and prospective interventional study) do not suggest direct or indirect harmful effects on influenza vaccines adjuvanted with MF59 with respect to pregnancy, fertility, embryonic/foetal development, parturition, or post natal development.
Preliminarni podaci iz spontano prijavljenih nuspojava i postmarketinških ispitivanja koja su u tijeku (registar trudnoća i buduća intervencijska studija) ne pokazuju izravne ili neizravne štetne učinke cjepiva protiv influence adjuvantiranih s MF59 u odnosu na trudnoću, plodnost, embrionalni/fetalni razvoj, porod ili postnatalni razvoj.
Preliminary data from spontaneously reported events and ongoing post-marketing studies (pregnancy registry and prospective interventional study) do not suggest direct or indirect harmful effects on influenza vaccines adjuvanted with MF59 with respect to pregnancy, fertility, embryonic/foetal development, parturition, or post natal development.
Preliminarni podaci spontano prijavljenih događaja i postmarketinških ispitivanja koja su u tijeku (registar trudnoća i prospektivna intervencijska studija) ne ukazuju na izravne ili neizravne štetne učinke cjepiva protiv influence adjuvantiranih s MF59 na trudnoću, plodnost, embrionalni/fetalni razvoj, porod ili postnatalni razvoj.
Preliminary data in children below 12 are consistent with those obtained in adolescents up to 17 years of age.
Preliminarni podaci u djece mlađe od 12 godina u skladu su s onima dobivenima u adolescenata u dobi do 17 godina.
Preliminary information suggests a relationship may exist between the presence of major deletion mutations in a patient's factor IX gene and an increased risk of inhibitor formation and of acute hypersensitivity reactions.
Preliminarne informacije ukazuju na mogući odnos između prisutnosti velikih delecijskih mutacija u genu bolesnika za faktor IX, i povećanog rizika od stvaranja inhibitora i akutnih reakcija preosjetljivosti.
Preliminary results from a supportive study (Study ELT116826), an ongoing non-randomised, phase II, single-arm, open-label study in refractory SAA subjects, showed consistent results.
Preliminarni rezultati iz potpornog ne-randomiziranog otvorenog ispitivanja faze II s jednom skupinom (ispitivanje ELT116826) u refrakternih ispitanika s teškom aplastičnom anemijom koje je trenutno u tijeku, pokazali su konzistentne rezultate.
Premature discontinuation with any antiplatelet therapy, including Brilique, could result in an increased risk of cardiovascular (CV) death or MI due to the patient’s underlying disease.
Prijevremeni prestanak uzimanja antitrombocitne terapije, uključujući i Brilique, može rezultirati povećanim rizikom od smrti uslijed kardiovaskularnog zatajenja ili infarkta miokarda zbog postojeće bolesti.
premature ejaculation
preuranjena ejakulacija
Premature fusion of the epiphyses has been reported in patients exposed to Erivedge.
Preuranjeno spajanje epifiza je zabilježeno u bolesnika koji su bili izloženi lijeku Erivedge.
Premature infants
Nedonoščad
Premature infants
Prerano rođena dojenčad
Premature infants who have already been transfused by the start of treatment with NeoRecormon are not likely to benefit as much as untransfused infants.
Nedonoščad koja je prethodno primila transfuziju, najvjerojatnije neće imati onoliku korist od liječenja lijekom NeoRecormon kao nedonoščad koja nije primila transfuziju.
Premature infants, for whom the corrected age of 5 weeks has not been reached (the corrected age being calculated by subtracting the number of weeks of prematurity from the actual age)
Prijevremeno rođena dojenčad, koja nisu dosegla korigiranu dob od 5 tjedana (korigirana dob se izračunava oduzimanjem broja tjedana od prijevremenog rođenja od stvarne dobi)
Premature menopause Ovarian failure**
Preuranjena menopauza Zatajenje jajnika
Premature ovarian failure confirmed by a specialist gynaecologist.
Prerano zatajivanje rada jajnika koje je potvrdio ginekolog.
Premature rupture of the membranes >30 weeks of gestation
Prijevremena ruptura vodenjaka >30 gestacijskog tjedna
Prematurely born babies (born between 27 and 36 weeks gestation) are given three doses with an interval of at least one month between each dose, with the first dose given at two months of age.
Prijevremeno rođena djeca (rođena između 27. i 36. tjedna gestacije) primaju tri doze u intervalima od najmanje mjesec dana između svake doze, pri čemu se prva doza daje u dobi od dva mjeseca.